MASH therapeutic drug
MASH Treatment Limitations
Rezdiffra (THR-β agonist) Limits
Fatty liver with
Inflammation & Fibrosis
Limited Efficacy
Complex Targets
Multiple complex
Multiple complex
IDN2401: THR-β & IL-11 Dual Targeting
Dual-target approach for comprehensive MASH treatment
natural product
anti-steatosis
Anti-steatosis
Via THR-β activation
anti-inflammation
Anti-inflammation
Via dual-target action
anti-fibrosis
Anti-fibrosis
Via IL-11 inhibition